On the subject in the title: Sulfonylureas: the interaction most worth taking seriously — what changed since Working notes rather than a conclusion.
What changes if the standard account of Sulfonylureas is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.
Working through the consequences rather than the evidence, since others here are better placed on the evidence.
Everything in the opening post holds. The case it does not cover is the one I have.
Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted. That is a reason for close monitoring, not for avoiding the combination.
I would put this at better than even and not much better.
Gastrointestinal symptoms from one compound can mask or mimic an interaction with another. Introducing two changes at once makes attribution impossible, which is an argument for spacing them.
Research-use-only compounds have no interaction data of any kind, because interaction studies are done on medicines being developed for use in people.
The arithmetic in post #2 is right; the assumption feeding it is the part to check.
SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
I have no interest in any supplier named above.
Supplements and herbs: many have no established interaction. Some do. If you are taking something unusual, checking a reference (like a pharmacist) is more useful than guessing from forum discussion.
Metformin: commonly co-administered and relevant to gastrointestinal tolerability. Gastrointestinal side effects can overlap and additive. Taking them separately or adjusting one if tolerability is poor are reasonable approaches.
That is the version I would defend. It is not the version I started with.
Where I part company with post #4, and it is a narrow parting.
Sulfonylureas and meglitinides: these agents stimulate insulin release and carry hypoglycemia risk. Combining them with semaglutide or tirzepatide requires dose adjustment of the secretagogue and close monitoring. The combination is not contraindicated but requires active management.
I have separated what I observed from what I concluded, which does not always happen.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] Antibiotics and a course of something with delayed emptying
On the subject in the title: Antibiotics and a course of something with delayed emptying Working notes rather than a conclusion. Something changed and I would like to know whether it should have. Same…
|
+88 | 97 | 19k | 13h |
|
Warfarin and altered intake: the monitoring argument
Warfarin and altered intake: the monitoring argument — setting out what I have, and where I think it stops being reliable. Proposing that warfarin and altered intake deserves a maintained page rather than a…
|
2 | 11k | 4mo | |
|
Warfarin and altered intake: the monitoring argument — the long version
Posting this under the heading it deserves: Warfarin and altered intake: the monitoring argument — the long version Everything below is what sits behind that. A narrow question about Warfarin and altered…
|
+123 | 134 | 40k | 4mo |
|
Follow-up: Reading an interaction checker output critically
Reading an interaction checker output critically — setting out what I have, and where I think it stops being reliable. A follow-up question about Reading an interaction checker output that I did not know to…
|
+62 | 66 | 13k | 2d |
|
Follow-up: Oral contraceptives and delayed emptying: what the data shows
Oral contraceptives and delayed emptying: what the data shows — setting out what I have, and where I think it stops being reliable. A follow-up question about Oral contraceptives and delayed emptying that I…
|
+31 | 35 | 13k | 18mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Personal or family history of medullary thyroid carcinoma — what changed since
Posting this under the heading it deserves: Personal or family history of medullary thyroid carcinoma — what changed since Everything below is what sits behind that. Asking about a contraindication as written…
|
+91 | 96 | 1.3k | 25d |
|
Hair shedding at month three: mechanism and time course
On the subject in the title: Hair shedding at month three: mechanism and time course Working notes rather than a conclusion. Reading back through what has been written here about hair shedding, three…
|
2 | 47k | 7mo | |
|
Delayed gastric emptying and oral medication absorption: which drugs matter
On the subject in the title: Delayed gastric emptying and oral medication absorption: which drugs matter Working notes rather than a conclusion. A follow-up question about delayed gastric emptying and oral…
|
+110 | 116 | 43k | 14mo |
|
Documenting an adverse event properly — the long version
Posting this under the heading it deserves: Documenting an adverse event properly — the long version Everything below is what sits behind that. A narrow question about Documenting an adverse event,…
|
+1 | 5 | 4.8k | 14mo |
|
Insulin combinations and hypoglycaemia risk
On the subject in the title: Insulin combinations and hypoglycaemia risk Working notes rather than a conclusion. I was wrong about insulin combinations and hypoglycaemia risk in a thread last spring and I…
|
+18 | 22 | 7.8k | 13mo |